Literature DB >> 4055049

Clinical evaluation of the effect of cefotaxime in senile pneumonia caused by gram-positive and gram-negative bacteria.

H Katsunuma.   

Abstract

66 patients with predominantly community-acquired pneumonia were treated with cefotaxime. The group consisted of 45 males and 21 females, aged 56 to 90 years, 43 of the patients belonging to the age groups 65-80 years. Streptococcus pneumoniae was isolated in 21 of the 34 patients with gram-positive pneumonia, Staphylococcus aureus in six, Staphylococcus epidermidis in five and Streptococcus faecalis in two. Klebsiella pneumoniae was the predominant pathogen in gram-negative pneumonia (eight patients), followed by Enterobacter (n = 6), Pseudomonas aeruginosa (n = 5), Haemophilus influenzae (n = 4), Escherichia coli (n = 3), Serratia marcescens and Citrobacter (two cases each). The in vitro activity of cefotaxime against the isolates was compared to the activity of other beta-lactam antibiotics. Characteristically, the classical signs and symptoms of pneumonia were absent or discrete in some of the elderly patients. There was a delayed clearance of pulmonary infiltrates. 55 of 66 patients responded to cefotaxime within four weeks of treatment; the symptoms were aggravated or remained unchanged in seven patients. Patients with a delayed clinical response displayed decreased peripheral lymphocyte counts and T cell functions in PHA stimulation tests, as well as low immunoglobulin levels. A combination of cefotaxime and gamma-venin cleared the symptoms in some of these patients.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4055049     DOI: 10.1007/BF01644212

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  9 in total

1.  Failure of resolution in pneumonia.

Authors:  D H Boyd
Journal:  Br J Dis Chest       Date:  1975-10

2.  Activity of HR 756 against Haemophilus influenzae, Bacteroides fragilis and Gram-negative rods.

Authors:  F A Drasar; W Farrell; A J Howard; C Hince; T Leung; J D Williams
Journal:  J Antimicrob Chemother       Date:  1978-09       Impact factor: 5.790

3.  Hospital study of adult community-acquired pneumonia.

Authors:  J T Macfarlane; R G Finch; M J Ward; A D Macrae
Journal:  Lancet       Date:  1982-07-31       Impact factor: 79.321

4.  [Supportive gamma-globulin therapy in refractory chronic respiratory tract infections].

Authors:  Y Shigeno
Journal:  Kansenshogaku Zasshi       Date:  1983-08

5.  In vitro investigation regarding the antibacterial effects of immunoglobulin alone and in combination with antibiotics.

Authors:  H Katsunuma
Journal:  Kansenshogaku Zasshi       Date:  1984-03

6.  [Clinical picture of acute phase of unresolved pneumonia].

Authors:  K Takamatsu; Y Nakano; H Komatsu; H Minamikawa; M Nishimoto; O Miyamoto
Journal:  Kansenshogaku Zasshi       Date:  1984-12

7.  HR 756, a new cephalosporin active against gram-positive and gram-negative aerobic and anaerobic bacteria.

Authors:  H C Neu; N Aswapokee; P Aswapokee; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1979-02       Impact factor: 5.191

8.  Pneumococcal pneumonia: experience in a community hospital.

Authors:  F E Smith; J M Mann
Journal:  West J Med       Date:  1982-01

9.  Relationship of patient age to clinical features and outcome for in-hospital treatment of pneumonia.

Authors:  A J Fedullo; A J Swinburne
Journal:  J Gerontol       Date:  1985-01
  9 in total
  2 in total

Review 1.  Treatment of respiratory tract infections with cephalosporin antibiotics.

Authors:  R Finch
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 2.  Cefotaxime. An update of its pharmacology and therapeutic use.

Authors:  P A Todd; R N Brogden
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.